Patient response to CAR-37 T cells. (A) Swimmer plot of patient’s responses to CAR-37 T cells. Two patients received HSCT as a consequence of cytopenia at the time points indicated by the diamonds. Other symbols indicate the cause of death for each patient, as noted. (B) Positron emission tomography (PET) scans of patients with CR, PR, or MR at the indicated time points. (C) Immunohistochemistry for CD37 in lesion biopsies before CAR T-cells infusion (preinfusion) and at the time of relapse by PET scan. Images were taken at 20×. (D) CD19, CD20, and CD37 expression in tumor from patient 1 as measured by flow cytometry performed by the clinical pathology laboratory. The purple dots and histogram represent the aberrant population. CTCL, cutaneous T-cell lymphoma; HGBCL, high-grade B-cell lymphoma; PD, progressive disease; PR, partial response.
Figure 2.

Patient response to CAR-37 T cells. (A) Swimmer plot of patient’s responses to CAR-37 T cells. Two patients received HSCT as a consequence of cytopenia at the time points indicated by the diamonds. Other symbols indicate the cause of death for each patient, as noted. (B) Positron emission tomography (PET) scans of patients with CR, PR, or MR at the indicated time points. (C) Immunohistochemistry for CD37 in lesion biopsies before CAR T-cells infusion (preinfusion) and at the time of relapse by PET scan. Images were taken at 20×. (D) CD19, CD20, and CD37 expression in tumor from patient 1 as measured by flow cytometry performed by the clinical pathology laboratory. The purple dots and histogram represent the aberrant population. CTCL, cutaneous T-cell lymphoma; HGBCL, high-grade B-cell lymphoma; PD, progressive disease; PR, partial response.

This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal